Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings

Key Takeaways Lilly's oncology sales are projected at $2.58B for Q3 2025, up over 15% year over year.Verzenio demand and pricing gains are expected to drive growth despite currency and competition.New drug Inluriyo won FDA approval but will not contribute sales until post-Q3 launch.While Eli Lilly (LLY) is a market leader in the GLP-1 segment, thanks to its tirzepatide medicines Mounjaro and Zepbound (for obesity), the company also generates a meaningful portion of revenues from its oncology franchise. Sale ...